Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection

H. Nakamura, Seitaro Fujishima, T. Inoue, Y. Ohkubo, Kenzo Soejima, Y. Waki, Masaaki Mori, T. Urano, F. Sakamaki, S. Tasaka, A. Ishizaka, M. Kanazawa, K. Yamaguchi

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The clinical and immunoregulatory effects of long-term macrolide antibiotic therapy for patients with chronic lower respiratory tract infections (CLRTI) were investigated. Clinical parameters and neutrophil chemotactic mediators in the epithelial lining fluid (ELF) of CLRTI patients (n=10) were examined before and after 3 months oral administration of roxithromycin (RXM). The in vitro effects of RXM were also examined on the release of these mediators from alveolar macrophages (AM) and neutrophils. Arterial oxygen tension (p<0.05), vital capacity (VC) (p<0.001), %VC (p<0.05) and forced expiratory volume in one second (p<0.01) were improved after RXM treatment, but airway bacteria were not eradicated. Among the mediators, the levels of interleukin (IL)-8, neutrophil elastase (NE) and leukotriene B4 (LTB4) were higher in ELF than in plasma of CLRTI patients and they decreased after RXM treatment (n=7, p<0.05 for each). RXM concentrations were significantly increased in the bronchoalveolar lavage cells of the treated patients. In in vitro experiments, RXM showed inhibitory effects on IL-8 release from AM and neutrophils. In conclusion, interleukin-8, neutrophil elastase and leukotriene B4 contribute to the neutrophilic inflammation in the airways of chronic lower respiratory tract infection patients and the clinical effects of roxithromycin may, in part, be attributable to the suppression of excess release of the chemotactic mediators from inflammatory cells.

Original languageEnglish
Pages (from-to)1371-1379
Number of pages9
JournalEuropean Respiratory Journal
Volume13
Issue number6
DOIs
Publication statusPublished - 1999

Fingerprint

Roxithromycin
Respiratory Tract Infections
Interleukin-8
Leukocyte Elastase
Neutrophils
Leukotriene B4
Vital Capacity
Alveolar Macrophages
Therapeutics
Macrolides
Forced Expiratory Volume
Bronchoalveolar Lavage
Oral Administration
Arterial Pressure
Oxygen
Anti-Bacterial Agents
Inflammation
Bacteria

Keywords

  • Chronic lower respiratory tract
  • Infections
  • Interleukin-8
  • Leukotriene B
  • Neutrophil elastase
  • Roxithromycin

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. / Nakamura, H.; Fujishima, Seitaro; Inoue, T.; Ohkubo, Y.; Soejima, Kenzo; Waki, Y.; Mori, Masaaki; Urano, T.; Sakamaki, F.; Tasaka, S.; Ishizaka, A.; Kanazawa, M.; Yamaguchi, K.

In: European Respiratory Journal, Vol. 13, No. 6, 1999, p. 1371-1379.

Research output: Contribution to journalArticle

Nakamura, H, Fujishima, S, Inoue, T, Ohkubo, Y, Soejima, K, Waki, Y, Mori, M, Urano, T, Sakamaki, F, Tasaka, S, Ishizaka, A, Kanazawa, M & Yamaguchi, K 1999, 'Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection', European Respiratory Journal, vol. 13, no. 6, pp. 1371-1379. https://doi.org/10.1034/j.1399-3003.1999.13f23.x
Nakamura, H. ; Fujishima, Seitaro ; Inoue, T. ; Ohkubo, Y. ; Soejima, Kenzo ; Waki, Y. ; Mori, Masaaki ; Urano, T. ; Sakamaki, F. ; Tasaka, S. ; Ishizaka, A. ; Kanazawa, M. ; Yamaguchi, K. / Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. In: European Respiratory Journal. 1999 ; Vol. 13, No. 6. pp. 1371-1379.
@article{6d464e9553dc44958ab2bc3d889a8249,
title = "Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection",
abstract = "The clinical and immunoregulatory effects of long-term macrolide antibiotic therapy for patients with chronic lower respiratory tract infections (CLRTI) were investigated. Clinical parameters and neutrophil chemotactic mediators in the epithelial lining fluid (ELF) of CLRTI patients (n=10) were examined before and after 3 months oral administration of roxithromycin (RXM). The in vitro effects of RXM were also examined on the release of these mediators from alveolar macrophages (AM) and neutrophils. Arterial oxygen tension (p<0.05), vital capacity (VC) (p<0.001), {\%}VC (p<0.05) and forced expiratory volume in one second (p<0.01) were improved after RXM treatment, but airway bacteria were not eradicated. Among the mediators, the levels of interleukin (IL)-8, neutrophil elastase (NE) and leukotriene B4 (LTB4) were higher in ELF than in plasma of CLRTI patients and they decreased after RXM treatment (n=7, p<0.05 for each). RXM concentrations were significantly increased in the bronchoalveolar lavage cells of the treated patients. In in vitro experiments, RXM showed inhibitory effects on IL-8 release from AM and neutrophils. In conclusion, interleukin-8, neutrophil elastase and leukotriene B4 contribute to the neutrophilic inflammation in the airways of chronic lower respiratory tract infection patients and the clinical effects of roxithromycin may, in part, be attributable to the suppression of excess release of the chemotactic mediators from inflammatory cells.",
keywords = "Chronic lower respiratory tract, Infections, Interleukin-8, Leukotriene B, Neutrophil elastase, Roxithromycin",
author = "H. Nakamura and Seitaro Fujishima and T. Inoue and Y. Ohkubo and Kenzo Soejima and Y. Waki and Masaaki Mori and T. Urano and F. Sakamaki and S. Tasaka and A. Ishizaka and M. Kanazawa and K. Yamaguchi",
year = "1999",
doi = "10.1034/j.1399-3003.1999.13f23.x",
language = "English",
volume = "13",
pages = "1371--1379",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "6",

}

TY - JOUR

T1 - Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection

AU - Nakamura, H.

AU - Fujishima, Seitaro

AU - Inoue, T.

AU - Ohkubo, Y.

AU - Soejima, Kenzo

AU - Waki, Y.

AU - Mori, Masaaki

AU - Urano, T.

AU - Sakamaki, F.

AU - Tasaka, S.

AU - Ishizaka, A.

AU - Kanazawa, M.

AU - Yamaguchi, K.

PY - 1999

Y1 - 1999

N2 - The clinical and immunoregulatory effects of long-term macrolide antibiotic therapy for patients with chronic lower respiratory tract infections (CLRTI) were investigated. Clinical parameters and neutrophil chemotactic mediators in the epithelial lining fluid (ELF) of CLRTI patients (n=10) were examined before and after 3 months oral administration of roxithromycin (RXM). The in vitro effects of RXM were also examined on the release of these mediators from alveolar macrophages (AM) and neutrophils. Arterial oxygen tension (p<0.05), vital capacity (VC) (p<0.001), %VC (p<0.05) and forced expiratory volume in one second (p<0.01) were improved after RXM treatment, but airway bacteria were not eradicated. Among the mediators, the levels of interleukin (IL)-8, neutrophil elastase (NE) and leukotriene B4 (LTB4) were higher in ELF than in plasma of CLRTI patients and they decreased after RXM treatment (n=7, p<0.05 for each). RXM concentrations were significantly increased in the bronchoalveolar lavage cells of the treated patients. In in vitro experiments, RXM showed inhibitory effects on IL-8 release from AM and neutrophils. In conclusion, interleukin-8, neutrophil elastase and leukotriene B4 contribute to the neutrophilic inflammation in the airways of chronic lower respiratory tract infection patients and the clinical effects of roxithromycin may, in part, be attributable to the suppression of excess release of the chemotactic mediators from inflammatory cells.

AB - The clinical and immunoregulatory effects of long-term macrolide antibiotic therapy for patients with chronic lower respiratory tract infections (CLRTI) were investigated. Clinical parameters and neutrophil chemotactic mediators in the epithelial lining fluid (ELF) of CLRTI patients (n=10) were examined before and after 3 months oral administration of roxithromycin (RXM). The in vitro effects of RXM were also examined on the release of these mediators from alveolar macrophages (AM) and neutrophils. Arterial oxygen tension (p<0.05), vital capacity (VC) (p<0.001), %VC (p<0.05) and forced expiratory volume in one second (p<0.01) were improved after RXM treatment, but airway bacteria were not eradicated. Among the mediators, the levels of interleukin (IL)-8, neutrophil elastase (NE) and leukotriene B4 (LTB4) were higher in ELF than in plasma of CLRTI patients and they decreased after RXM treatment (n=7, p<0.05 for each). RXM concentrations were significantly increased in the bronchoalveolar lavage cells of the treated patients. In in vitro experiments, RXM showed inhibitory effects on IL-8 release from AM and neutrophils. In conclusion, interleukin-8, neutrophil elastase and leukotriene B4 contribute to the neutrophilic inflammation in the airways of chronic lower respiratory tract infection patients and the clinical effects of roxithromycin may, in part, be attributable to the suppression of excess release of the chemotactic mediators from inflammatory cells.

KW - Chronic lower respiratory tract

KW - Infections

KW - Interleukin-8

KW - Leukotriene B

KW - Neutrophil elastase

KW - Roxithromycin

UR - http://www.scopus.com/inward/record.url?scp=0032792527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032792527&partnerID=8YFLogxK

U2 - 10.1034/j.1399-3003.1999.13f23.x

DO - 10.1034/j.1399-3003.1999.13f23.x

M3 - Article

C2 - 10445614

AN - SCOPUS:0032792527

VL - 13

SP - 1371

EP - 1379

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 6

ER -